TABLE 1

Patients’ Characteristics

Patient no.	Age (y)	Sex	Myeloma type	Disease duration	IMID	PI	Auto SCT	BM involvement at time of PET (%)	Serum M protein (g/L)	Involved serum FLC level (mg/L)	¹⁸F-FDG PET	No. of FL	¹¹C-methionine PET	No. of FL
¹⁸F-FDG–negative
1	67	M	IgG λ	14	Yes	Yes	Yes	15	29.2	20.4	Neg	—	Pos	20
2	56	M	IgA κ	32	Yes	Yes	Yes	40	44.7	0.5	Neg	—	Pos	>50
3	63	M	LC λ	0	No	No	No	15	0	444	Neg	—	Pos	>50
4	62	M	IgG κ	199	Yes	Yes	Yes	20	13.0	14,015	Neg	—	Pos	>50
5	53	F	LC κ	122	Yes	Yes	Yes	15	0	99	Neg	—	Pos	6
6	63	F	LC λ	23	No	Yes	Yes	10	0	1,876	Neg	—	Pos	>50
7	53	F	LC λ	11	Yes	Yes	No	20	0	3,396	Neg	—	Pos	>50
8	64	M	LC κ	54	Yes	Yes	Yes	25	0	1,183	Neg	—	Pos	16
9	62	F	IgG κ	39	Yes	No	Yes	10	1.7	955	Neg	—	Pos	5
¹⁸F-FDG–positive
C1	64	M	IgG κ	4	No	Yes	No	40	51.1	293	Pos	>50	Pos	>50
C2	63	M	LC κ	0	No	No	No	70	0	14,014	Pos	>50	Pos	>50
C3	51	M	IgG κ	34	Yes	Yes	Yes	60	24.6	828	Pos	>50	Pos	>50
C4	73	M	IgG κ	72	Yes	Yes	Yes	70	4.7	25,100	Pos	>50	Pos	>50
C5	63	F	IgG κ	22	Yes	Yes	Yes	30	47.5	1,907	Pos	>50	Pos	>50
C6	53	M	LC λ	57	Yes	Yes	Yes	0^*	0	105	Pos	>50	Pos	>50

↵* Sampling error.
IMID = immunomodulatory drugs; PI = proteasome inhibitors; auto SCT = autologous stem cell transplantation; BM = bone marrow; FLC = free light chain; FL = focal lesions on PET/CT; neg = negative; pos = positive.
Disease duration is given in months (patients 3 and C2 presented with newly diagnosed disease). Bone marrow involvement was assessed by histologic evaluation of random iliac crest biopsy samples.